NUVISAN The Science CRO
Daniel Korr is currently the Head of Therapeutic Compound Research Laboratory at NUVISAN The Science CRO. Prior to this, Daniel held various positions at Bayer, including as Head of Oncology Research Laboratory. Daniel has a Ph.D. in Biochemistry from Schering AG and has a strong background in oncology research.
This person is not in the org chart
NUVISAN The Science CRO
1 followers
Founded in Europe with more than 40 years of experience, NUVISAN is a fully integrated contract research and development, and manufacturing organization (CRO/CDMO) that offers unique, high-quality, and tailored integrated solutions along the drug discovery and development value chain. With more than 1.000 employees distributed over six locations in Germany and France including our drug discovery hub in Berlin as well as with local experts situated in Latin America, NUVISAN is pleased to offer the following portfolio of services: • Drug discovery & research - Discovery pharmacology - Discovery bioscience - Screening - Life science chemistry - Translation research - Digital life science - Toxicology - DMPK • Non-clinical studies • Pharmaceutical analysis • Topical formulation development • Chemical development with GMP manufacturing (3-10kg) • Bioanalytical labs • GMP manufacturing (up to 50Kg) • Clinical trial supplies • Phase 1 and 2 clinical studies and beyond Our services can be provided as stand-alone or integrated solutions and can be customized to your project. Email us at hello@nuvisan.com for more.